# Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled

> **NCT01699932** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 167 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Glimepiride+metformin (Amaryl M®) - HOE4900

## Key facts

- **NCT ID:** NCT01699932
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2014-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01699932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01699932, "Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01699932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*